Merck & Co., Inc.
  • home
  • Newsroom
  • licensing
  • Contact Us
  • About Us
    • Our Values
    • Leadership
    • How We Operate
    • Our History
  • Responsibility
    • Philanthrophy/
      Donations
  • Merck Research Home
    • Discovery And Development Process At Merck
    • Canada-Specific Research
  • Merck Product
    • Vaccines
    • Prescription Products
    • Consumer Products
    • Animal Health
  • Careers
    • Search And Apply For Jobs
    • Explore Careers
    • Life At Merck

  • MERCK IN CANADA  Learn more

    Today's Merck is working to help the world be well. Merck is a global health care leader with a diversified portfolio of prescription medicines, vaccines, consumer and animal health products. In Canada, Merck markets more than 530 pharmaceutical, consumer and animal health products. Merck is a leader in a broad range of areas such as cardiology, infectious diseases, respiratory, vaccines, women's health and sun care, and is focused on expanding offerings in other areas, including virology, oncology and diabetes.

  • LATEST NEWS   Visit the newsroom
    • June 10, 2013
      Merck Applauds This Year's Bourse Fernand-Seguin Recipients
    • May 24, 2013
      Merck Employees Pull Together for Women's and Maternal Health from Vancouver, B.C., to Montréal, QC
    • May 9, 2013
      GARDASIL® Available to Developing Countries through UNICEF Tender
    • April 22, 2013
      Merck invests in pan-Canadian life sciences research innovation sector
  • WORKING AT MERCK   Learn more

    We want to make Merck the pharmaceutical company of choice by recruiting, training and managing the best people. Visit our careers section to learn more about who we are as a company and to discover the many reasons to join Merck.

  
  • Patients & Caregivers
    • Merck Manuals
  • Healthcare Professionals
    • Merck Manuals
    • Univadis
  • Other
    • Copyright
    • Privacy
    • Terms of Use
    • Site Map
    • Careers
    • Terms & Conditions for Sales
  • Global Links
    • Merck.com Global Site
    • Investors
    • Global Newsroom
    • Licensing
    • Pipeline